NCT00319930View on ClinicalTrials.gov

Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2005

Study Completion Date

May 31, 2007

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

CNF1010 (17-AAG)

Trial Locations (6)

12208

Albany

29605

Greenville

34761

Ocoee

45409

Dayton

75702

Tyler

85258

Norfolk

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00319930 - Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL | Biotech Hunter | Biotech Hunter